MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallStory so far
Earlier from Mesoblast
- DSMB Recommends Continuation of Phase 3 COVID-19 Trial
- ODAC Votes in Favor of Remestemcel-L for GvHD
- Update on Scheduled FDA Advisory Committee Meeting
- COVID-19/GVHD Update, Quarterly Report and Appendix 4C
- FDA Advisory Committee Sets Review Date for Remestemcel-L
Later from Mesoblast
- COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
- DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
- First Quarter Results Presentation
- Novartis and Mesoblast Remestemcel-L Collaboration
- Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast